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1. Introduction 
5-Fluoro- (I) and Schloro- (II) pyrimidin-2-one 
has been shown to exhibit metaphase-arresting 
activity [ 1,2]. 
R=-F (I) 
R=-Cl (II) 
R= -Br (III) 
H R=-H (IV) 
We have now extended our work on this class of 
substances and have attempted to establish the 
structure-activity relationship. The results suggest 
that the metaphase-inhibitory activity is associated 
with the 2-0~0 group and the 5-halogen, and that 
certain substituents in other positions are permissable 
for the retainment of activity. We should like to 
suggest he name Metahalones for this class of 
inhibitors. Meta from metaphase, ha2 from halogen 
and one because the activity is associated with the 
one-form of the 2-hydroxy group; O-substituted deriv- 
atives as shown below are inactive whereas 
N-substituted derivates are active. 
2. Materials and methods 
The substances tested were synthesized by methods 
described in the references (see table 1,2). All sub- 
stances were tested for metaphase-arresting activity 
6 h after addition to monolayer cultures of the Chang 
strain of human liver cells. The methods used have been 
detailed in [ 11. The substances were tested over a 
range of concentrations. The following terms are used 
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for describing the activity of the substances: 
Complete arrest: there were no ana- and telophases 
and accumulation of cells in metaphase. 
Significant metaphase arrest: the arrest was only 
partial with some ana- and telophases but with a 
significant increase in the number of cells in 
metaphase. Approximately 100% increase of that 
in the control cells was considered significant. 
No metaphase arrest: there was no significant 
difference between the number of cells in 
metaphase, anaphase and telophase in the treated 
and controls. 
3. Results and discussion 
A number of pyrimidin-2-ones with substituents 
other than halogen in the 5-position were tested. It is 
seen from table 1 that the 5 substituents, -CHs (V), 
-CHaOH (VI), -CN (VII), -NOa (VIII) and -S03H 
(IX), did not produce a substance with metaphase- 
arresting activity at 2-3 mM whereas 5-halogeno- 
pyrimidin-2-ones (I, II, III) exhibit significant 
metaphase-arresting activity (table 2). As shown in 
[I], pyrimidin-2-one (IV) did not exhibit any activ- 
ity even at 8 mM. Hence the results suggest hat the 
5-halogen substituent is required for activity. 
R = -CHs 
/ R 
0 
R = -CH20H :; 
0’ N 
R= -CN (VII) 
H R = -NO2 (VIII) 
R = -SOaH (IX) 
Furthermore, it is seen from table 1 that the 
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Table 1 
Effect of substances on Chang iiver cells 
~--- 
Substances No metaphase 
arrest at (mM) 
Pyrimidin-2-one (IV) I11 8 
S-Methylpyrimidin-2-one (V) I121 2 
S-Hydroxymethylpyrimidin-2-one (VI) I121 2 
5-Cyanopyrimidin-2-one (VII) I131 3 
5-Nitropyrimidin-2-one (VIII) iI41 2 
S-Sulfopyrimidin-2-one (IX) I151 2 
5-Chloropyr~rnidin-4-one (X) (171 2 
2-~Iethox~S-~uoropyrimid~ne (XI) 1201 3 
2-Methoxy-S-chloropyrimidine (XII) 1181 3 
2-Mcthoxy-S-bromopyrimidine (XIII) I191 3 
2-Amino-S-chloropyrimidine (XIV) I161 2 
2-Hydrazino-S-chloropyrimidine (XV) I161 3 
2-Methylthio-S-chloropyrimidine (XVIII) I2OJ 3 
2-Methy~fhio-j-bromopyrimjdine (XIX) PII 3 
5Chlorouracil (XXV) I171 2 
I-Propargyl-5-tlurouracil (XXVI) [8l 3 
4-Ethoxy-S-fluoropyrimidin-2-one (XXVII) 131 3 
___~_ __~ 
position of the oxygen atom in the pyrimidine ring 
relative to the halogen atom is critical since 
5-c~oropyrirnidin~-one (X) is inactive. The one- 
form of the 2-hydroxy groups is necessary for 
activity since the methoxy group (XI, XII, XIII) in 
the 2-position results in inactive substances (table 1). 
0 
R2 
IX) 
RI = -OCH3 R2 = -F (XI) 
Rr = -0CHs Rs = -Ci (XII) 
Rr = -0CHs Rz = -Br (XIII) 
R, = -NH2 R2 = -Cl (XIV) 
R, = -NHNH2 Rz = -Cl (XV) 
R= -Cl (XVI) 
R=-Br (XVII) 
introducing an amino group into the 2-position 
(XIV) resulted in an inactive molecule (table 2). The 
2-hydrazino derivative (XV) was also inactive but 
toxic. 
When replacing the oxygen with sulphur (XVI, 
XVII) substances with significant metaphase-inhibitory 
activity at 3 mM were obtained (table 2). S-Alkylation 
(XVIII, XIX, formulae not shown) leads to inactive 
substances (table 1). 
~kylat~on of the I-position {XX, XXI, XXII) in 
the 5.halogenopyrimidin-2-ones results in metaphase 
arresting substances. Certain substituents such as the 
Table 2 
Effect of substances on Chang liver cells 
.---. ----_ ----_____-.___~__-_ 
Substances Complete 
metaphase 
arrest at 
(mM) 
-.-_I~_-- -- __-- 
S-Fluoropyrimidin-2-one (I) 1 31 1.75 
5-Chloropyrimidin-2-one (II) t 41 2.0 
5-Bromopyrimidin-2-one (HI) I Sl 
S-Cl~ioro~?yri~~~idin-2-ti~ione (XVI) I 61 
5-Bro~~~opyrir~~idin-2-tl~ione (XVII) I 81 
l-Methyl-S-fluoropyrimidin-z-one (XX) i 71 3.0 
l-Methyl-S-chioropyrimidin-2-one (XXI) I 71 2.0 
1-Methyl-S-bramopyrimidin-2-one (XXII) l 51 3.0 
I-Proparpyld-chloropyrimidin-Lone (XXIII) I 81 0.18 
l-~-I~i~~arobc~yl-S~l~ioropyrimidin-2-one (XXIV) [ 81 0.25 
4-Metl~yi-5-brolnopyrimidin-2-one (XXVIII) I 91 3.0 
4-Methyithio-S-tluoropyrimidin2-one (Xxix) /lOI 
I ,4-DimethyWbromopyrimidin-2-one (XXX) [ 91 2.0 
4,6-Dimethyl-5-bromopyrimidin-2-one (XxX1) Ill1 1.5 
_~l- -_ 
Significant 
metaphase 
arrest at 
(mM) 
0.87 
0.50 
3.0 
3.0 
3.0 
1.5 
1.0 
1.5 
0.09 
0.125 
0.75 
3.0 
1.0 
0.75 
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propargyl (XXIII) and p-fluorobenzyl (XXIV) will 
result in more active substances as compared with 
the parent compound (table 2). 
Rt = -F 
Rt = -Cl 
Ri = -Br 
Rt = -Cl 
R1 = -Cl 
Rz = -CHa 
Rz = -CHs 
Ra = -CH3 
R2 = -CH,-C-CH 
R2 = -CHaC6H4-p-F 
(XX) 
(XXI) 
(XXII) 
(XXIII) 
(XXIV) 
Substitu~ons in the 4.position may and may not 
result in metaphase-arresting substances. S-Chlorouracil 
(XXV), 1-propargyl-5-fluorouracil (XXVI), as well 
as 4-ethoxy-5-fluorouracil (XXVII) were inactive at 
3 mM (table I). On the other hand substituents such 
as the methyl group (XXVIII) and the me~ylthio 
group (XXIX) gave substances with some activity 
(table 2). Introduction of two methyl groups in the 
1,4- or 4,6-position (XXX and XXXI), respectively, 
gave substances with metaphase-arresting activity 
(table 2). 
R, = -OH R2 = -Cl 
Ra = -H R‘,=-H 
Ri = -OH 
Rs=-H 
R, = -OC2HS 
Rs = -H 
Ra = -F 
R4 = -CHa-C-CH 
R2 = -F 
&=-H 
R1 = -CHs 
Rs=-H 
R2 = -Br 
%=-H 
Rt = -SCHs 
Ra=-H 
Rz = -F 
IQ=-H 
NW 
(xxw 
(=w 
(XXVIII) 
(XXVIII) 
RI = -CHs 
Rs = -H 
Rs = -Br 
IQ = -CHa (XXX> 
Ri = -CHs Ra = -Br 
Ra = -CHs %=-H @XXI) 
The data presented show that substitution in the 
5-position is a prerequisite for activity since 
pyrimidin-2-one even at 8 mM exhibited no activity. 
A number of substances with substituents in the 
5-position, however, such as, methyl-, hydroxy- 
methyl-, cyano-, nitro- and sulpho-, showed no 
metaphase arresting activity at the dose level where, 
i.e., the 5-chloro- and S-fluoropyrimidin-2-one 
exhibit complete arrest. These results uggest that the 
5-h~ogen substituent in the py~midin-2-one 
molecule is required for activity. Furthermore, in the 
case of 1 -propargyl-5-chloropyrimidin2.one (XXIII) 
which gives complete metaphase arrest at 0.18 mM, 
the parent substance, i.e., I-propargylpyrimidin-2- 
one (8 (at 3 mM), result not included in tables) at 
about 17-times the above concentration isdevoid of 
metaphase arresting activity. This again underlines the 
necessity of the 5-halogen substituent. 
Another essential feature of the molecule for 
metaphase-arresting activity is the 2-one or 2-thione 
structure since 0 and ~-methylation or substitution 
at C-2 with other groups yield inactive substances. 
It is seen from table 2 that substituents such as 
propargyl and p-fluorobenzyl will increase the 
activity more than 1 order of magnitude. In the case 
of the latter substance, the presence of the bulky 
p-~uoroben~yl group has no adverse ffect on the 
activity. Furthermore, it is interesting to note that 
the propargyl group itself confers no metaphase- 
arresting activity to the molecule since 1 -propargylJ- 
fluorouracil and 1 -propargylpyrimidin-2-one exhibit 
no activity at nearly 20-times higher concentration. 
The nature of a substituent in the 4-position seems 
to be critical since the hydroxy group or the ethoxy 
group gives molecules with no activity at the 3 mM 
level. On the other hand, a methyl or a methylthio 
group in the 4-position does not abolish activity. 
Several classes of substances are known to arrest 
cells in metaphase. The best known are colchicine 
[22], the vinca alkaloids, vinblastine and vincristine 
[22], podophyllotoxin [23] and steganacin [24]. 
Recently, a new metaphase-arresting agent 
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nocadazole was also reported [25]. All these sub- 
stances arrest cells in metaphase apparently by con- 
densing with the microtubular protein vital for the 
formation of the spindle apparatus. 
Another metaphase inhibitor, 5-substituted 
3-( 1 -anilinoethylidinyl) pyrrolidine-2,4-dione has 
also been described [26]. 
The structure of the metahalones is quite 
unrelated to the metaphase inhibitors described 
above. Their structure is also less complex. 
The mode of action of the metahalones is not 
yet known but preliminary data with 5-chloro- 
pyrimidin-2-one could suggest hat it combines with 
tubulin [27]. 
The concentration of the metahalones required to 
obtain complete metaphase arrest is, however, several 
order of magnitudes higher than that found for the 
most-used metaphase inhibitors such as colchinine 
and the vinca alkaloids. However, the present results 
indicate that it is possible to increase the activity by 
suitable substitution in the 5-halogenopyrimidin-2- 
one molecule. It is also worth mentioning that the 
activity of the substance seems to depend on the cell 
system used. For instance, using sea urchin egg, it 
was found that 5-chloropyrimidin-2-one at 20 PM was 
sufficient to achieve complete metaphase arrest [28]. 
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